| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development expenses | 2,585 | |||
| Selling, general and administrative expenses | 2,298 | |||
| Loss from operations | -4,883 | |||
| Realized gains from sales of trading securities | 208 | |||
| Unrealized gain (loss) from trading securities | -39 | |||
| Interest income, net | 175 | |||
| Total other income | 344 | |||
| Net loss | -4,539 | |||
| Basic | 20,155,000 | |||
| Diluted | 20,155,000 | |||
| Net loss per basic common share | -0.23 | |||
| Net loss per diluted common share | -0.23 | |||
enVVeno Medical Corp (NVNO)
enVVeno Medical Corp (NVNO)